孟鲁司特钠联合布地奈德治疗支气管哮喘效果的探讨.docVIP

孟鲁司特钠联合布地奈德治疗支气管哮喘效果的探讨 　　[摘要] 目的 探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的临床效果。方法 方便选择2016年1月―2017年5月该院收治的支气管哮喘患者130例，根据随机数表法将所有患者分为两组，每组各65例。对照组予以布地奈德治疗，观察组在此基础上予以孟鲁司特钠联合治疗，观察比较两组治疗前后第1秒肺活量/用力肺活量（FEV1/FVC）、最大呼气流速率（PEF）]指标、哮喘发作次数及治疗效果。结果 治疗前两组FEV1/FVC、PEF水平及哮喘发作次数相比，差异无统计学意义（P0.05）；治疗后对照组FEV1/FVC、PEF水平低于观察组，哮喘发作次数多于观察组，差异有统计学意义（P0.05）；对照组治疗总有效率为70.77%，明显低于观察组的96.92%，差异有统计学意义（P0.05）；两组治疗期间未见不良反应发生。结论 孟鲁司特钠联合布地奈德可有效改善支气管哮喘患者肺功能，减少哮喘发生次数，提高治疗效果，安全副作用小。 　　[关键词] 孟鲁司特钠；布地奈德；支气管哮喘；临床疗效 　　[中?D分类号] R4 [文献标识码] A [文章编号] 1674-0742（2017）10（c）-0127-03 　　Effect of Montelukast Sodium Combined with Budesonide on Bronchial Asthma 　　ZHANG Run-juan 　　Department of Respiratory Medicine， Guangxi Zhuang Autonomous Region Nationalities Hospital， Nanning， Guangxi， 530001 China 　　[Abstract] Objective This paper tries to investigate the clinical effect of montelukast sodium combined with budesonide in the treatment of bronchial asthma. Methods Convenient selection 130 patients with bronchial asthma from January 2016 to May 2017 in this hospital were enrolled in this study. All patients were divided into two groups according to the random number table method. FEV1 / FVC and the maximum expiratory flow rate （PEF）， number of asthma attacks and the curative efficacy were measured before and after treatment in the first second of two groups before and after treatment. Results There were no significant differences in FEV1 / FVC， PEF levels between the two groups before the treatment（P0.05）. After treatment， the levels of FEV1 / FVC and PEF were lower than the control group（P0.05）. The number of asthma attacks in the observation group was more than that in the control group（P0.05）. The total effective rate was 70.77% in the control group， which was significantly lower than that in the observation group of 96.92%（P0.05）. There were no adverse reactions in both groups during the treatment. Conclusion Montelukast sodium combined with budesonide can effectively improve the pulmonary function in patients with bronc